Taiwan · Delayed Price · Currency is TWD Anbogen Therapeutics Company Description
Anbogen Therapeutics, Inc. develops precision anti-cancer drugs and conducts research and development in oncology.
The company develops precision oncology drugs, including clinical-stage assets such as ABT-101 for non-small cell lung cancer with HER2 exon20 insertion mutations and ABT-301 for metastatic colorectal cancer in combination with anti-PD-1 therapies.
It conducts clinical trials to evaluate the safety, tolerability, and efficacy of its drug candidates, including combination therapies with immune checkpoint inhibitors.
The company manages a research and development platform and pipeline for advancing cancer therapies and collaborates with pharmaceutical companies for drug-supply agreements.
Anbogen Therapeutics serves pharmaceutical companies, oncology-focused biopharmaceutical companies, diagnostic firms, research institutes, and clinical research organizations.
The company was founded in 2019 and is based in Taipei, Taiwan.
| Country | Taiwan |
| Founded | 2019 |
| Industry | Pharmaceutical Preparations |
Contact Details
Address: C523, No.99, Lane 130, Sec. 1 Taipei, 11571 Taiwan | |
| Phone | 886 2 8979 8616 |
| Website | anbogen.com |
Stock Details
| Ticker Symbol | 7784 |
| Exchange | Taipei Exchange |
| Reporting Currency | TWD |
| SIC Code | 2834 |